Online citations, reference lists, and bibliographies.
← Back to Search

Absorption Enhancers For Nasal Drug Delivery

S. Davis, L. Illum
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper describes the basic concepts for the transmucosal delivery of drugs, and in particular the use of the nasal route for delivery of challenging drugs such as polar low-molecular-weight drugs and peptides and proteins. Strategies for the exploitation of absorption enhancers for the improvement of nasal delivery are discussed, including consideration of mechanisms of action and the correlation between toxic effect and absorption enhancement. Selected enhancer systems, such as cyclodextrins, phospholipids, bioadhesive powder systems and chitosan, are discussed in detail. Examples of the use of these enhancers in preclinical and clinical studies are given. Methods for assessing irritancy and damage to the nasal membrane from the use of absorption enhancers are also described. Finally, the mucosal use of absorption enhancers (chitosan) for the improved nasal delivery of vaccines is reported with reference to recent phase I/II clinical studies.
This paper references
10.1016/0306-4522(91)90355-R
c-FOS-like immunoreactivity in rat brainstem neurons following noxious chemical stimulation of the nasal mucosa
F. Anton (1991)
10.1023/A:1011908128045
Recent Advances in Intestinal Macromolecular Drug Delivery via Receptor-Mediated Transport Pathways
P. Swaan (2004)
10.1007/BF00401839
Intranasal insulin therapy: the clinical realities
J. Hilsted (2004)
10.3109/03639049409038397
Drug Permeation Enhancement - Theory and Applications
D. Hsieh (1994)
10.1016/0168-3659(96)01357-0
The influence of absorption enhancers on intranasal insulin absorption in normal and diabetic subjects
F. W. H. M. Merkus (1996)
10.1016/S0885-3924(02)00522-5
Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer.
H. Pavis (2002)
10.1016/S0378-5173(97)04914-4
The effect of chronic nasal application of chitosan solutions on cilia beat frequency in guinea pigs
T. Aspden (1997)
Intranasal administration of beta-interferon in rabbits.
Y. Maitani (1986)
10.1002/JPS.2600841104
DS-1, a modified Quillaja saponin, enhances ocular and nasal absorption of insulin.
D. Pillion (1995)
10.1016/0169-409X(92)90001-7
(D) Routes of delivery: Case studies
P. Edman (1992)
10.1016/0378-5173(94)00365-C
Morphological examination of rabbit nasal mucosa after exposure to acetylsalicylic acid, glycofurol 75 and ephedrine
E. Bindseil (1995)
Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance.
D. Lalej-Bennis (2001)
10.1080/00016489950182025
Validation of animal experiments on ciliary function in vitro. II. The influence of absorption enhancers, preservatives and physiologic saline.
W. Boek (1999)
10.1042/CS0780215
A comparison of the acute effects of subcutaneous and intranasal calcitonin.
D. O'Doherty (1990)
10.1152/AJPGI.1993.265.5.G955
Regulation of paracellular permeability in Caco-2 cell monolayers by protein kinase C.
W. Stenson (1993)
10.3109/10611869909085518
Improved nasal bioavailability of FITC-dextran (Mw 4300) from mucoadhesive microspheres in rabbits.
M. A. El-shafy (2000)
10.1016/S0168-3659(97)00101-6
Acylated non-α-amino acids as novel agents for the oral delivery of heparin sodium, USP
A. Leone-Bay (1998)
10.1111/j.1464-5491.1995.tb00464.x
Intranasal Insulin: the Effects of Three Dose Regimens on Postprandial Glycaemic Profiles in Type II Diabetic Subjects
P. Coates (1995)
10.1023/A:1007594602449
Biovector™ Nanoparticles Improve Antinociceptive Efficacy of Nasal Morphine
D. Betbeder (2004)
10.1023/A:1018970006935
Nasal Absorption in the Rat. III. Effect of Lysophospholipids on Insulin Absorption and Nasal Histology
Susan G. Chandler (2004)
Intranasal toxicity of selected absorption enhancers.
N. Haffejee (2001)
10.1016/S0169-409X(98)00054-4
Cyclodextrins in nasal drug delivery.
Merkus (1999)
10.1016/S0168-3659(01)00540-5
The enhancing effect of nasal absorption of FITC-dextran 4,400 by β-sitosterol β-d-glucoside in rabbits
Kouji Nakamura (2002)
Ophthalmic and nasal delivery of insulin from oily suspensions in rabbits in vitro and in vivo
T. Yamamoto (1994)
10.1097/00005537-200104000-00008
Classification of Cilio‐Inhibiting Effects of Nasal Drugs
P. Merkus (2001)
10.1023/A:1015904404442
Absorption Enhancement of Intranasally Administered Insulin by Sodium Taurodihydrofusidate (STDHF) in Rabbits and Rats
M. J. Deurloo (2004)
10.1023/A:1015808023310
Nasal Membrane and Intracellular Protein and Enzyme Release by Bile Salts and Bile Salt-Fatty Acid Mixed Micelles: Correlation with Facilitated Drug Transport
Z. Shao (2004)
10.1081/DDC-100102275
The relationship between the rigidity of the liposomal membrane and the absorption of insulin after nasal administration of liposomes modified with an enhancer containing insulin in rabbits.
K. Muramatsu (1999)
10.1016/S0264-410X(98)00077-2
Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice.
I. Jabbal‐Gill (1998)
10.1023/A:1011952804479
Nasal Absorption Kinetic Behavior of Azetirelin and Its Enhancement by Acylcarnitines in Rats
S. Kagatani (2004)
10.1016/0168-3659(94)90080-9
The potential of cyclodextrins as absorption enhancers in nasal delivery of peptide drugs
J. Verhoef (1994)
Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter.
B. Aungst (1988)
10.1128/IAI.71.2.726-732.2003
Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin A
K. Mills (2003)
10.1016/S0378-5173(00)00506-8
Lipid emulsions as vehicles for enhanced nasal delivery of insulin.
R. Mitra (2000)
10.1016/0169-409X(92)90002-8
(D) Routes of delivery: Case studies
J. Patton (1992)
10.1080/107175499266823
Toxicological Implications of Nasal Formulations
M. Quadir (1999)
10.1023/A:1016444808000
Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells
N. G. Schipper (2004)
10.1016/S0169-409X(98)00073-8
Intranasal insulin delivery and therapy.
Hinchcliffe (1999)
10.3109/10717549809031388
The influence of the enhancer dimyristoylphosphatidylglycerol and formulation factors on the nasal absorption of salmon calcitonin.
R. Dua (1998)
10.3109/10611869808995865
Absorption enhancers as tools to determine the route of nasal absorption of peptides.
A. Donnelly (1998)
10.1016/0928-0987(95)00026-7
Chitosan as a nasal delivery system: evaluation of insulin absorption enhancement and effect on nasal membrane integrity using rat models
T. Aspden (1996)
10.1016/S0169-409X(97)00064-1
Optimization of systemic nasal drug delivery with pharmaceutical excipients.
Roméo (1998)
Bioadhesive polymers as intranasal drug delivery systems for peptide and protein drugs.
R. Soane (1999)
10.1016/0378-5173(93)90167-E
Effect of absorption promoters on the nasal absorption of drugs with various molecular weights
A. Yamamoto (1993)
10.1016/0378-5173(90)90149-X
The influence of insulin and some excipients used in nasal insulin preparations on mucociliary clearance
S. Gizurarson (1990)
10.1016/0928-0987(94)90017-5
Cyclodextrins as protection agents against enhancer damage in nasal delivery systems II. Effect on in vivo absorption of insulin and histopathology of nasal membrane
I. Gill (1994)
10.1023/A:1011975721569
Dodecylmaltoside-Mediated Nasal and Ocular Absorption of Lyspro-Insulin: Independence of Surfactant Action from Multimer Dissociation
D. Pillion (2004)
10.1016/S0169-409X(97)00069-0
Microspheres as nasal drug delivery systems.
Pereswetoff-Morath (1998)
10.1111/j.2042-7158.1994.tb03876.x
Nasal Absorption of Desmopressin in Rats and Sheep. Effect of a Bioadhesive Microsphere Delivery System
H. Critchley (1994)
10.1111/j.2042-7158.1998.tb03319.x
Biopharmaceutics: Cytotoxicity of Absorption Enhancers in Caco‐2 Cell Monolayers
M. Sakai (1998)
10.1023/A:1015838508656
Relationship Between Drug Absorption Enhancing Activity and Membrane Perturbing Effects of Acylcarnitines
E. Lecluyse (2004)
10.1016/S0378-5173(99)00019-8
Intranasal absorption of melatonin in vivo bioavailability study.
E. Bechgaard (1999)
10.3109/10611869808995876
Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes.
T. Lindmark (1998)
10.1007/BF00318047
Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin
N. G. Schipper (2004)
10.1016/S1461-5347(98)00100-X
Macromolecules as safe penetration enhancers for hydrophilic drugs—a fiction?
H. Junginger (1998)
10.1002/JPS.2600841108
Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats.
K. Matsubara (1995)
10.1016/0378-5173(91)90344-N
Nasal absorption in rats. II. Effect of enhancers on insulin absorption and nasal histology
Susan G. Chandler (1991)
10.1128/IAI.68.10.5764-5770.2000
Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens
A. Bacon (2000)
Correlation between the sensitivity of the ciliary beat frequency of human adenoid tissue and chicken embryo tracheas for some drugs.
H. van de Donk (1982)
Nasal formulations of ketorolac tromethamine: technological evaluation--bioavailability and tolerability in rabbits.
G. Santus (1993)
10.1016/0378-5173(80)90045-9
An approach to the evaluation of hygroscopicity for pharmaceutical solids
L. V. Campen (1980)
10.1248/CPB.43.2232
Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-beta-cyclodextrin.
K. Abe (1995)
10.1016/S0168-3659(98)00115-1
The effect of methylated beta-cyclodextrins on the tight junctions of the rat nasal respiratory epithelium: electron microscopic and confocal laser scanning microscopic visualization studies.
E. Marttin (1999)
The effects of preservatives on the ciliary beat frequency of chicken embryo tracheas.
H. van de Donk (1980)
10.1016/0378-5173(94)00308-R
Nasal absorption in the rat. IV: Membrane activity of absorption enhancers
Susan G. Chandler (1995)
10.1023/A:1016051600828
Enhancement of Nasal Salmon Calcitonin Absorption by Lauroylcarnitine Chloride in Rats
S. Kagatani (2004)
10.1111/j.1464-5491.1992.tb01792.x
Intranasal Administration of Insulin With Phospholipid as Absorption Enhancer: Pharmacokinetics in Normal Subjects
K. Drejer (1992)
10.1023/A:1015847604654
Cyclodextrins as Nasal Absorption Promoters of Insulin: Mechanistic Evaluations
Z. Shao (2004)
Toxicological evaluation of intranasal peptide and protein drugs
M. Dorato (1994)
10.1016/0168-3659(92)90018-M
Microspheres as a nasal delivery system for peptide drugs
P. Edman (1992)
Systemic delivery of peptides and proteins across absorptive mucosae.
Sayani Ap (1996)
10.1023/A:1014801714590
Gastropods as an Evaluation Tool for Screening the Irritating Potency of Absorption Enhancers and Drugs
E. Adriaens (2004)
10.1111/j.1464-5491.1991.tb01611.x
Meal‐time Intranasal Insulin Delivery in Type 2 Diabetes
D. Bruce (1991)
10.1023/A:1015894910416
Effects of Viscous Hyaluronate–Sodium Solutions on the Nasal Absorption of Vasopressin and An Analogue
K. Morimoto (2004)
10.1016/0378-5173(94)00293-E
The effect of soybean-derived sterol and its glucoside as an enhancer of nasal absorption of insulin in rabbits in vitro and in vivo
Y. Maitani (1995)
10.1210/JCEM-72-2-344
Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women.
K. Overgaard (1991)
10.1248/BPB.21.866
High absorbency and subchronic morphologic effects on the nasal epithelium of a nasal insulin powder dosage form with a soybean-derived sterylglucoside mixture in rabbits.
T. Yamamoto (1998)
10.1111/j.2042-7158.1985.tb05024.x
Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel
K. Morimoto (1985)
10.1248/BPB.16.93
Absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and blood leukocyte dynamics following intranasal administration in rabbits.
Y. Watanabe (1993)
10.1016/S0378-5173(01)00708-6
Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides.
L. Illum (2001)
10.2337/diab.42.11.1649
The Pharmacodynamics and Activity of Intranasally Administered Insulin in Healthy Male Volunteers
M. Jacobs (1993)
10.1007/BF02974223
Effect of sodium taurodihydrofusidate on nasal drug delivery: Differences in its concentration and penetrant molecular weight
K. Hosoya (1994)
10.1016/S1461-5347(99)00199-6
Delivery of peptide and non-peptide drugs through the respiratory tract.
Davis (1999)
10.1111/j.1365-2265.1994.tb02491.x
Serum growth hormone (GH) profiles after nasally administered GH in normal subjects and GH deficient patients
Jens Maller (1994)
10.1016/S0169-409X(97)00066-5
Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption.
Huang (1998)
10.1111/j.1398-9995.1997.tb02528.x
Permeation of polysucrose 15 000 across the human nasal mucosa in vivo
M. Andersson (1997)
10.1089/JIR.1990.10.497
Nasal absorption of interferon: enhancement by surfactant agents.
C. Baglioni (1990)
10.1023/A:1018915710318
Effect of Formulation Additives upon the Intranasal Bioavailability of a Peptide Drug: Tetracosactide (ACTH1−24)
P. Wüthrich (2004)
10.3109/10611869808997878
Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs.
E. Marttin (1998)
10.1046/J.1365-2125.1999.00894.X
Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks.
K. Roon (1999)
Effect of insulin concentration on bioavailability during nasal spray administration.
P. Valensi (1996)
10.1016/S0378-5173(98)00367-6
Evaluation of the clearance characteristics of bioadhesive systems in humans.
R. Soane (1999)
10.1016/S0169-409X(01)00171-5
Chitosan as a novel nasal delivery system for vaccines.
L. Illum (2001)
10.1023/A:1016488623022
Mucoadhesive Polymers in Peroral Peptide Drug Delivery. VI. Carbomer and Chitosan Improve the Intestinal Absorption of the Peptide Drug Buserelin In Vivo
H. L. Luessen (2004)
10.1023/A:1018901302450
Chitosan as a Novel Nasal Delivery System for Peptide Drugs
L. Illum (2004)
10.1023/A:1015850310589
Enhancement of Nasal Delivery of a Renin Inhibitor in the Rat Using Emulsion Formulations
T. Kararli (2004)
10.1055/S-2007-1004876
Biological activity of nasally administered insulin in normal subjects.
M. Nolte (1990)
10.1016/S0168-3659(99)00271-0
Evaluation of starch-maltodextrin-Carbopol 974 P mixtures for the nasal delivery of insulin in rabbits.
C. Callens (2000)
10.1016/S0378-5173(99)00470-6
The enhancing effect of soybean-derived sterylglucoside and β-sitosterol β-d-glucoside on nasal absorption in rabbits
Y. Maitani (2000)
10.1172/JCI118114
Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro.
A. Fasano (1995)
10.1016/S0378-5173(97)00364-5
The effect of a viscosity and an absorption enhancer on the intra nasal absorption of metoprolol in rats
N. Kilian (1998)
10.1021/LA001754U
Chitosan-Induced Perturbation of Dipalmitoyl-sn-glycero-3-phosphocholine Membrane Bilayer
Vincent Chan (2001)
10.1038/nbt1201-1173
A peptide carrier for the delivery of biologically active proteins into mammalian cells
M. Morris (2001)
10.1021/BK-2000-0752.CH003
Safe Mucosal Penetration Enhancers: A Fiction?: Polymers as Absorption Enhancers for Transmucosal Drug Delivery
H. Junginger (2000)
10.1021/JS960182O
Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers.
T. Aspden (1997)
10.1016/S0378-5173(99)00451-2
Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts.
P. Tengamnuay (2000)
10.1023/A:1011929016601
Chitosan and its use as a pharmaceutical excipient.
L. Illum (1998)
10.1016/S0168-3659(97)00253-8
Nasal delivery of peptides: an in vitro cell culture model for the investigation of transport and metabolism in human nasal epithelium.
T. Kissel (1998)
Optimization effects of hydroxypropyl-β-cyclodextrin in combination with nasal absorption enhancer HPE-101
T. Irie (1996)
Novel chitosan-based delivery systems for the nasal administration of a LHRH-analogue
L. Illum (2000)
10.1023/A:1015880502548
Interspecies Differences in the Nasal Absorption of Insulin
F. W. H. M. Merkus (2004)
10.3109/10611869509015941
Mucosal penetration enhancement.
H. Sezaki (1995)
10.1016/S0168-3659(97)00193-4
Microparticle resins as a potential nasal drug delivery system for insulin.
M. Takenaga (1998)
10.1211/0022357021778367
Aminated gelatin as a nasal absorption enhancer for peptide drugs: evaluation of absorption enhancing effect and nasal mucosa perturbation in rats
J. Wang (2002)
10.1046/j.1468-2982.1997.1704541.x
Safety, Tolerability, and Pharmacokinetics of Sumatriptan in Healthy Subjects Following Ascending Single Intranasal Doses and Multiple Intranasal Doses
K. Moore (1997)
10.1016/S0378-5173(01)00602-0
Clearance characteristics of chitosan based formulations in the sheep nasal cavity.
R. Soane (2001)
10.1016/S0264-410X(00)00309-1
A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
E. McNeela (2000)
10.1016/0378-5173(94)90105-8
Site-dependence and structure-effect relationships for alkylglycosides as transmucosal absorption promoters for insulin
B. Aungst (1994)
10.1016/S0169-409X(97)00061-6
In vitro cell models to study nasal mucosal permeability and metabolism.
Merkle (1998)
10.2165/00003088-199223010-00003
Intranasal Insulin
L. Illum (1992)
10.1016/S0928-0987(01)00146-4
Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol.
M. Bagger (2001)
10.1124/JPET.301.1.391
Intranasal delivery of morphine.
L. Illum (2002)
10.1016/S0928-0987(00)00087-7
Transport of drugs from the nasal cavity to the central nervous system.
L. Illum (2000)
10.1248/BPB1978.12.31
Promotion of nasal absorption of insulin by glycyrrhetinic acid derivatives. I.
M. Mishima (1989)
10.1002/JPS.2600800803
Intranasal bioavailability of insulin powder formulations: effect of permeation enhancer-to-protein ratio.
W. Lee (1991)
10.1023/A:1016235705448
A Semisynthetic Quillaja Saponin as a Drug Delivery Agent for Aminoglycoside Antibiotics
J. Recchia (2004)
10.1016/0378-5173(95)00050-S
Combined use of 2-hydroxypropyl-β-cyclodextrin and a lipophilic absorption enhancer in nasal delivery of the LHRH agonist, buserelin acetate, in rats
K. Abe (1995)
10.1023/A:1015885204249
The Effect of Sodium Tauro-24,25-Dihydrofusidate on the Nasal Absorption of Human Growth Hormone in Three Animal Models
Patricia A. Baldwin (2004)
10.1021/JS970134J
Molecular structure of the apical junction complex and its contribution to the paracellular barrier.
K. Lutz (1997)
10.1016/S0169-409X(97)00065-3
Prodrugs for nasal drug delivery.
Mitra (1998)
10.3109/10611860008996864
Absorption Enhancement of a Protein Drug by Nitric Oxide Donor: Effect on Nasal Absorption of Human Granulocyte Colony-Stimulating Factor
Y. Watanabe (2000)
10.1023/A:1018999414088
Nasal Insulin Delivery with Dimethyl-β-Cyclodextrin as an Absorption Enhancer in Rabbits: Powder More Effective than Liquid Formulations
N. G. Schipper (2004)
10.1124/JPET.301.1.1
Pharmacology and toxicology of astrocyte-neuron glutamate transport and cycling.
U. Sonnewald (2002)
10.1152/AJPLUNG.1996.271.4.L646
Effects of a short-chain phospholipid on ion transport pathways in rabbit nasal airway epithelium.
M. Röpke (1996)
10.1016/S0955-2863(01)00208-X
The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line(1).
G. Ranaldi (2002)
10.3109/10837459609022593
Oramucosal delivery of LHRH: pharmacokinetic studies of controlled and enhanced transmucosal permeation.
S. Nakane (1996)
Experimental studies on acute and chronic action of azelastine on nasal mucosa in guinea pigs, rats and dogs.
U. Achterrath-Tuckermann (1997)
10.1023/A:1018967116988
Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2)
P. Artursson (2004)
10.1016/0168-3659(84)90017-8
Powder dosage form of insulin for nasal administration
Nagai Tsuneji (1984)
10.1023/A:1015896405389
Absorption Enhancing Effect of Cyclodextrins on Intranasally Administered Insulin in Rats
F. H. H. M. Merkus (2004)
10.1177/106002809402800703
Nasal Absorption of Growth Hormone in Normal Subjects: Studies with Four Different Formulations
T. Laursen (1994)
10.1016/0378-5173(93)90395-V
Effects of insulin and nasal absorption enhancers on ciliary activity
L. Jian (1993)
10.1016/0378-5173(93)90020-G
Ammonium glycyrrhizinate (AMGZ) effects on membrane integrity
P. M. Reardon (1993)
10.1021/JS980233C
Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments: in vitro evaluation in intestinal epithelial cells (Caco-2).
A. Kotzé (1999)
10.1016/0378-5173(95)04385-3
Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: Comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations
F. Sakr (1996)
10.1023/A:1015904730599
The Molecular Weight Dependence of Nasal Absorption: The Effect of Absorption Enhancers
M. Donovan (2004)
10.1016/S0168-3659(01)00553-3
Development of a novel nasal nicotine formulation comprising an optimal pulsatile and sustained plasma nicotine profile for smoking cessation.
Y. Cheng (2002)
In vivo studies on nasal preparations of ciprofloxacin hydrochloride.
Y. Ozsoy (2000)
10.1210/ENDO.135.6.7988421
Insulin delivery in nosedrops: new formulations containing alkylglycosides.
D. Pillion (1994)
10.1210/JCEM.76.4.8473411
Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
L. Hedin (1993)
10.1023/A:1018990318090
Absorption of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) from Rat Nasal Mucosa
M. Machida (2004)
10.1016/S0378-5173(99)00100-3
Screening of cationic compounds as an absorption enhancer for nasal drug delivery.
H. Natsume (1999)
10.1016/S0168-3659(02)00363-2
Nasal drug delivery--possibilities, problems and solutions.
L. Illum (2003)
10.1023/A:1012160102740
Chitosans as Absorption Enhancers for Poorly Absorbable Drugs 2: Mechanism of Absorption Enhancement
N. G. Schipper (2004)
10.1016/S0378-5173(99)00030-7
Effect of chitosan on epithelial permeability and structure.
V. Dodane (1999)
10.1023/A:1015884026056
Nasal Absorption Enhancers for Biosynthetic Human Growth Hormone in Rats
D. O'hagan (2004)
10.1016/0378-5173(96)04569-3
Nasal delivery of octreotide: Absorption enhancement by particulate carrier systems
C. Oechslein (1996)



This paper is referenced by
10.1016/J.ADDR.2004.09.004
Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery.
H. O. Alpar (2005)
10.1007/s11095-019-2610-y
Mathematical Modeling and Simulation to Investigate the CNS Transport Characteristics of Nanoemulsion-Based Drug Delivery Following Intranasal Administration
Ekta Kadakia (2019)
20 Nasal Delivery of Peptide Drugs
D. Pillion (2006)
10.1080/03639040600712953
Transport Characteristics of a Beta Sheet Breaker Peptide Across Excised Bovine Nasal Mucosa
A. Greimel (2007)
Nanotecnología Farmacéutica: Una galénica emergente
J. L. V. Jato (2006)
10.1016/j.xphs.2019.07.012
Effect of glyceryl monocaprylate modified chitosan on the intranasal absorption of insulin in rats.
Mingyue Gao (2019)
10.1016/j.jconrel.2008.09.076
Effect of cell-penetrating peptides on the nasal absorption of insulin.
E. Khafagy (2009)
10.1016/B978-012397632-1/50007-1
CHAPTER 6 – Neurosurgical Targeting, Delivery, and Infusion of Gene Therapy Agents in the Brain
J. Fraser (2006)
10.1016/j.ejps.2009.07.003
Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery.
Amjad Alhalaweh (2009)
10.4155/tde.13.104
Basics and recent advances in peptide and protein drug delivery.
Benjamin J. Bruno (2013)
10.1089/JAM.2006.19.92
Nasal clearance in health and disease.
L. Illum (2006)
Linear and Branched Chitosan Oligomers as Delivery Systems for pDNA and siRNA In Vitro and In Vivo
M. M. Issa (2006)
10.1016/J.IJPHARM.2006.07.038
Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation.
N. M. Zaki (2006)
BIOLOGICAL RESEARCH CENTER OF THE HUNGARIAN
S. Horvát (2009)
NOVEL NASAL MICROCAPSULAR DELIVERY SYSTEM OF GALANTAMINE HYDROBROMIDE
S. Patel (2012)
Nasal Drug Delivery-A Pre Hospital Therapy in Status Epilepsy-Review
ChitraKarthikeyini (2016)
Effect of some intranasal formulations used in the management of allergic rhinitis on mucociliary function
Marwa M. R. R. Ayoub (2015)
10.3390/pharmaceutics11100540
Liposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives
Soon-Seok Hong (2019)
10.1039/c3cs60436e
Emerging micro- and nanotechnology based synthetic approaches for insulin delivery.
Ran Mo (2014)
10.1016/J.IJPHARM.2006.07.040
Rapid-onset intranasal delivery of metoclopramide hydrochloride. Part I. Influence of formulation variables on drug absorption in anesthetized rats.
N. M. Zaki (2006)
10.1089/jamp.2008.0727
Use of flexible weighted nasal spray dip tubes to improve product performance.
Diane V Doughty (2010)
Nasal delivery of peptides using powder carriers based on starch/poly(acrylic acid)
E. Pringels (2006)
10.1002/jps.21924
Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
S. Dhuria (2010)
10.1248/YAKUSHI.130.1115
[Enhancement of insulin absorption through mucosal membranes using cationic polymers].
T. Seki (2010)
10.1002/JPS.20510
Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery.
S. Chen (2006)
10.1016/J.IJPHARM.2007.02.004
Effects of a sperminated gelatin on the nasal absorption of insulin.
T. Seki (2007)
10.1089/JAMP.2015.1252
Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model.
RyggAlex (2016)
10.3109/9781420006629-10
Dosage Form Considerations in Preformulation
Sarfaraz K Niazi (2006)
10.1016/B0-08-045044-X/00050-X
Peptide and Protein Drugs: Issues and Solutions
J. J. Nestor (2007)
Nasal drug delivery system: A innovative approach
Syed G A Moinuddin (2019)
10.1007/s13346-012-0086-y
Microparticles based on chitosan/pectin polyelectrolyte complexes for nasal delivery of tacrine hydrochloride
B. Saladini (2012)
10.1016/j.biomaterials.2011.11.068
Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization.
You-Bin Wu (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar